What are the potential treatment options?
Frits van Rhee, MD, PhD, University of Arkansas for Medical Sciences, says that in this patient one would like to exclude that the Herpesvirus type 8 is not active. Molecular testing is a necessity, which detects replicating virus in the peripheral blood. Ten to 20% of the American population is infected with this virus, and it’s dormant, asleep, and not causing problems. The antibody test may be positive for this virus in 10-20% of patients, and it’s not informative. What one must look for is either replicating virus, dividing virus in the peripheral blood, or stain the lymph node for active virus. These tests were negative in this patient. That would point to a diagnosis of HHV negative, or what’s also referred to now as idiopathic multicentric Castleman’s disease. The term idiopathic in medicine is used to indicate that it is truly known as to what is causing the disease.
Guess the Diagnosis: Case 2
Mark F. is a 25-year-old law school student from Florida with a 3-week history of severe fatigue, night sweats, and weight loss; he has also reported high fevers for the past week. He did not complain of joint pain.
The patient was admitted for further assessment.
Mark’s SLE diagnosis was reviewed and further testing was performed:
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More